39 published articles
The 2026 Abdul-Hafez et al narrative review (PMC12824524) establishes tirzepatide as a dual GIP/GLP-1 receptor co-agonist with five mechanistically distinct cardiovascular pathways. In the SUMMIT trial, it reduced the composite of cardiovascular death or worsening heart failure by 38% in obese HFpEF patients. Protocol designers must map each pathway to a separate interaction node.
Yuan et al. (MDPI, 2026) characterise BPC-157 as operating across two separable axes — a regenerative axis anchored in VEGFR2–Akt–eNOS signalling and FAK/paxillin fibroblast activation, and an analgesic axis running through nitric oxide modulation and dopaminergic–opioid interaction. For stack designers, each axis creates a distinct interaction node: compounds converging on the same pathway require co-administration scrutiny.
The 2026 Pharmaceuticals critical analysis (DOI: 10.3390/ph19020297) establishes that semaglutide produces tissue-specific GLP-1R outputs: cardioprotective in myocardium, proliferative in thyroid C-cells under rodent conditions. For cardio-oncology stack design, this dual signal means the compound can be a rational co-administration partner with anthracycline-class agents while requiring hard exclusion in thyroid-risk populations — two decisions made in parallel, not sequentially.
No controlled human trial has tested BPC-157 plus TB-500 co-administration for torn ligament recovery as of 2026. The combination rationale is mechanistically coherent — the two compounds operate through non-overlapping repair pathways — but the additive-effect claim rests entirely on preclinical single-compound data and uncontrolled self-experimentation reports. No combined benefit has been formally quantified in any ligament model.
GLP-1 receptor agonists and AOD-9604 operate through non-overlapping receptor systems — GLP-1R–mediated central appetite suppression versus β3-adrenergic–driven peripheral lipolysis — making direct receptor competition structurally impossible. No co-administration RCT exists as of 2026. Sequencing logic is built from each compound's independent pharmacokinetics: AOD-9604's ~4-minute serum half-life versus semaglutide's ~168-hour half-life defines the only meaningful timing variable.
Retatrutide adds glucagon receptor (GCGR) agonism to the GLP-1R/GIPR dual-agonist framework, driving hepatic fatty acid oxidation and thermogenic energy expenditure. Phase 3 TRIUMPH-1 data show approximately 28% mean weight loss at 80 weeks, exceeding dual-agonist benchmarks. Protocol designers must account for a longer titration schedule and a hepatic-fat reduction vector absent in dual-agonist stacks.
Incretin mimetics — GLP-1R and GIPR agonists — acutely suppress AgRP neuron firing in the arcuate nucleus, short-circuiting the orexigenic signal that normally amplifies hunger when circulating leptin falls during caloric restriction. This neural override partially decouples fasting adherence from the leptin-depletion cascade, though it does not prevent the absolute leptin decline accompanying fat-mass loss.
The 2026 bibliometric and evidence-based review (PMC13068985) of tirzepatide in MASH does more than catalogue clinical outcomes — its co-citation clusters and keyword co-occurrence maps identify which mechanistic hypotheses are research-active, which compound pairings are evidence voids, and where the field's next interaction data will emerge. Protocol designers can read this topology as a forward-looking interaction map.
Published in Lancet Regional Health–Europe in 2026, the Yazdanfard et al. cohort study tracked 879 type 1 diabetes (T1D) individuals who initiated semaglutide against 3,516 matched controls from Danish national registries. The compound produced a 5.7 mmol/mol HbA1c reduction with no elevated hypoglycaemia hospitalisation rate, indicating meaningful glycaemic benefit in selected T1D individuals despite current regulatory caution.
The 2026 bibliometric and evidence-based review (PMC13068985) confirms that tirzepatide — a dual GIP/GLP-1 receptor agonist — produces MASH resolution in 44–62% of participants across dose arms versus 10% placebo, with fibrosis-stage improvement in 55–62% versus 30% placebo. Its dual incretin mechanism distinguishes it from single-agonist comparators in protocol design.
The FDA's Pharmacy Compounding Advisory Committee (PCAC) convened July 23–24, 2026 to evaluate BPC-157 and TB-500 for the 503A Bulk Drug Substances List — a regulatory gate, not an approval. Inclusion would permit licensed compounding pharmacies to prepare these peptides under individual prescriptions, but it does not alter WADA's prohibition, eliminate immunogenicity concerns, or validate any specific athlete recovery protocol.
A 2026 critical analysis published in Pharmaceuticals (MDPI) maps two competing off-target profiles for semaglutide: a context-dependent oncogenic signal concentrated in thyroid C-cells and pancreatic tissue, and a robust cardioprotective mechanism that attenuates chemotherapy-induced and ischemia-driven cardiac injury via GLP-1 receptor–mediated PI3K/AKT and NF-κB suppression. Protocol designers must account for both vectors simultaneously.